Ultragenyx Pharmaceutical investors who purchased shares between August 3, 2023 and December 26, 2025 have until April 6, 2026 to apply for lead plaintiff status in Bailey v. Ultragenyx Pharmaceutical Inc., a federal securities class action lawsuit filed in the U.S. District Court for the Northern District of California (Case No. 3:26-cv-01097).
This deadline marks a critical window for shareholders who suffered losses following the company’s December 29, 2025 announcement that two Phase III clinical trials for its flagship drug setrusumab failed to achieve their primary endpoints, triggering a 42% stock price collapse. Investors with losses exceeding $100,000 are being specifically targeted by claims administrators, though the lawsuit encompasses all eligible shareholders who held NASDAQ: RARE stock during the relevant investment period. This article explains what the April 6 deadline means, why the lawsuit was filed, who qualifies as a class member, and what steps investors need to take to protect their rights. Understanding the requirements and timeline is essential because missing this deadline eliminates your opportunity to serve as a lead plaintiff—a position that allows larger shareholders to have direct input on the case strategy and settlement terms.
Table of Contents
- What Is the April 6, 2026 Deadline for Ultragenyx Class Action Filings?
- Understanding the Setrusumab Clinical Trial Failures
- The Stock Price Collapse and Investor Impact
- How to Apply for Lead Plaintiff Status
- What Investors Should Know About Class Action Timeline
- Determining If You Qualify as a Class Member
- What Happens After the Lead Plaintiff Deadline
- Frequently Asked Questions
What Is the April 6, 2026 Deadline for Ultragenyx Class Action Filings?
The April 6, 2026 deadline is the final date for eligible investors to submit applications to the court requesting consideration as a lead plaintiff in the Ultragenyx securities class action. A lead plaintiff is a shareholder with significant financial losses who represents all class members in the lawsuit, working alongside the attorneys to approve settlements and major case decisions. This deadline is distinct from later dates that will apply to the broader class of investors—for example, claim submission deadlines typically come months after a settlement is finalized, often occurring years after a case begins.
The lead plaintiff application process is the first critical juncture where individual investor action is required. To qualify for lead plaintiff status, you must file a declaration with the court demonstrating that you meet the legal requirements: you must be a member of the class (having purchased Ultragenyx stock during August 3, 2023 through December 26, 2025), you must have suffered an investment loss, and you must be prepared to serve as a representative of the class. The court will select the lead plaintiff based on factors like the size of investment losses and commitment to the role. Unlike settling a claim later, becoming a lead plaintiff requires active participation in the lawsuit, which is why firms like Kessler Topaz Meltzer & Check and Faruqi & Faruqi are actively recruiting investors with substantial losses to submit applications.
Understanding the Setrusumab Clinical Trial Failures
The lawsuit stems from disappointing Phase III clinical trial results announced on December 29, 2025. Ultragenyx was developing setrusumab, a monoclonal antibody intended to treat variable types of Osteogenesis Imperfecta (OI), a genetic disorder characterized by fragile bones and frequent fractures. The company ran two parallel Phase III studies—the Orbit and Cosmic trials—to demonstrate that setrusumab could reduce the rate of new fractures in OI patients compared to existing treatments (placebo or bisphosphonates). Both studies failed to achieve statistical significance on their primary endpoint: a meaningful reduction in annualized clinical fracture rate.
This was not a minor shortfall or expected outcome; it was a fundamental failure of the drug’s core efficacy claim. The clinical failure was particularly damaging because Ultragenyx had built its investment case around setrusumab’s promise for OI patients, many of whom have limited treatment options and suffer from profound disability. investors had been told the drug showed strong potential based on earlier-stage data, and the company’s market value partially reflected expectations of regulatory approval and commercial success. When the Phase III results came back negative, those expectations evaporated. The stock plummeted 42%, wiping out billions in shareholder value. For investors who had held the stock through multiple years anticipating positive trial results, this outcome represented a catastrophic loss of capital.
The Stock Price Collapse and Investor Impact
The 42% stock price decline following the December 29, 2025 announcement represents one of the most severe single-day impacts from a clinical trial failure in recent pharmaceutical history. An investor who purchased 1,000 shares of Ultragenyx at an average price of $100 per share during the relevant period would have experienced a loss of approximately $42,000 on that investment alone—enough to potentially qualify for lead plaintiff consideration if losses topped $100,000. The class action allegations contend that this loss was partly preventable because Ultragenyx allegedly misrepresented information about setrusumab’s efficacy and downplayed the risks of clinical trial failure. However, not all shareholders experienced losses of equal magnitude.
Investors who purchased shares late in the claim period (closer to December 2025) would have paid higher prices and suffered larger percentage losses. Investors who purchased at lower prices earlier in the period might have experienced smaller absolute dollar losses. The 42% decline also doesn’t tell the full story of individual losses—some investors held through previous Ultragenyx developments that may have already reduced the stock price, while others exited positions before the announcement. Class membership is determined by the investment period, not by individual timing, so even investors who sold shares before December 29 and avoided the full 42% decline may still qualify if they purchased during the lawsuit period.
How to Apply for Lead Plaintiff Status
To apply for lead plaintiff status, you need to file a declaration (a sworn legal statement) with the court before April 6, 2026. You’ll need to provide documentation showing: (1) the dates you purchased Ultragenyx stock, (2) the number of shares purchased, (3) the price paid, (4) when and at what price you sold (or if you still hold shares), and (5) your total investment loss. This should be supported by brokerage statements or account records that prove your ownership. You’ll also need to confirm your willingness to participate in the case, respond to discovery requests, and potentially testify if the case goes to trial (though most securities class actions settle before trial). The law firms managing the case—such as Kessler Topaz Meltzer & Check, Faruqi & Faruqi, and others—typically make the application process straightforward.
They provide templates, instructions, and support to help investors prepare their declarations. However, one critical caveat: some investors attempt to exaggerate losses or manipulate records to appear more qualified. The court reviews all submissions, and providing false information can expose you to perjury charges. Additionally, if you hire an attorney to help you apply, you may incur legal fees, whereas the lead plaintiff attorneys work on a contingency basis (they’re paid from the eventual settlement). Before spending money on separate legal representation, contact one of the firms handling the case directly—they want large-loss investors to apply and typically provide free assistance.
What Investors Should Know About Class Action Timeline
The April 6 deadline is just the beginning of what will be a lengthy process. After the court selects a lead plaintiff, the next phase is discovery, during which both the plaintiff and Ultragenyx exchange documents, conduct depositions, and build their cases. This phase typically lasts 12-18 months. During this time, the defendant may file motions to dismiss or summary judgment motions, which can delay or derail the case entirely. A landmark securities class action can take 3-5 years from filing to final settlement, meaning Ultragenyx investors may not see compensation until 2028 or 2029 at the earliest.
This extended timeline is important for investors to understand because it affects their financial planning—you’re not getting a check next month. One frequently misunderstood aspect of class actions: even if you miss the lead plaintiff deadline, you can still file a claim once a settlement is reached, provided the settlement notice period hasn’t closed. However, missing the April 6 deadline means you forfeit the opportunity to influence the lawsuit strategy, approve settlements, or ensure your interests are fully represented at the highest decision-making level. Additionally, statutes of limitations on securities claims require that the lawsuit be filed within a certain window—in this case, because the complaint was filed in January 2026 after the December 29 announcement triggered the discovery of the alleged wrongdoing, the timing was within legal requirements. But if you wait too long before claiming membership as a shareholder, you could find yourself time-barred from recovery if the case proceeds without you.
Determining If You Qualify as a Class Member
Class membership for the Ultragenyx action is relatively straightforward to determine but requires you to have clear records. You qualify if you purchased or acquired common shares of Ultragenyx (NASDAQ: RARE) at any time between August 3, 2023 and the close of trading on December 26, 2025, and you are not an excluded party (such as the company’s directors, officers, or their immediate family members in some circumstances). If you bought shares in a retirement account like a 401(k) or IRA, you still qualify—the class includes shares held in any account type. If your shares were held in a brokerage account, a managed account, or through an employee stock plan, you’re eligible.
One important clarification: you must have been harmed by the stock price decline. If you purchased shares at $50 and they declined to $20, you have a loss. If you purchased at $120 and they’re now worth $70, you have a loss. But if you somehow purchased shares at $10 before August 3, 2023 and held them through the claim period without buying more, you wouldn’t have incurred any loss on those original shares during the claim period—though any additional purchases made between August 3, 2023 and December 26, 2025 would count toward your loss calculation. The calculation of losses can be complex when investors have made multiple purchases at different prices, which is why keeping detailed brokerage statements is critical.
What Happens After the Lead Plaintiff Deadline
Once the April 6 deadline passes and the court appoints a lead plaintiff, the case enters the substantive litigation phase. The lead plaintiff works with the attorneys to develop the case, negotiate with Ultragenyx’s legal team, and approve any settlement. For other class members who didn’t apply for lead plaintiff status, your involvement at this stage is minimal—you’ll receive settlement notifications once an agreement is reached, but you won’t have direct control over the negotiations. This is why lead plaintiff status is valuable to investors with large losses: it gives you a voice in determining what happens next.
Looking ahead, the securities bar and pharmaceutical industry are increasingly scrutinized for clinical trial representations. Regulators and plaintiffs’ attorneys are paying close attention to whether companies like Ultragenyx adequately disclosed clinical risks in advance of trial results. While this Ultragenyx case will play out over years, investors should be aware that claims involving failed drug trials, missed efficacy endpoints, or misrepresented clinical data have become a focal point for shareholder litigation. If you held Ultragenyx stock during the relevant period and experienced losses, the April 6 deadline is your final chance to shape how that claim is handled.
Frequently Asked Questions
Can I apply for lead plaintiff status if I’ve already sold my Ultragenyx shares?
Yes. The class is defined by shares purchased during the claim period, not by current ownership. If you bought shares between August 3, 2023 and December 26, 2025, and sold them at a loss before or after the December 29 announcement, you’re eligible to apply. The law is designed this way because shareholders who exited positions can still have suffered harm from being misled during their ownership period.
What happens if I apply for lead plaintiff status and don’t get selected?
You remain part of the class action. You’ll receive settlement notifications when a settlement is reached and can file a claim to recover a portion of your losses, just like other non-lead-plaintiff class members. Being passed over for lead plaintiff status doesn’t disadvantage you in the final settlement calculation—all class members are treated equally when funds are distributed.
Are there attorney fees I have to pay if I apply for lead plaintiff status?
No. The lead plaintiff attorneys work on a contingency basis, meaning they only get paid if the case settles or succeeds at trial, and their fees come from the settlement fund before distributions to class members. You don’t pay upfront. However, the court must approve their fee request, and a portion of the settlement (typically 25-30%) is reserved for attorney compensation.
Will applying for lead plaintiff status expose my personal information to Ultragenyx?
Your application to the court becomes part of the case record, and under normal discovery rules, both parties (the plaintiff and Ultragenyx) will have access to information about class members. However, courts typically allow confidentiality protections for personal financial information if requested. Discuss any privacy concerns with the plaintiff law firm before submitting.
What if I can’t locate my old brokerage statements from 2023?
Contact your brokerage or financial institution. They maintain records of all transactions for at least six years, even if you’ve closed the account or moved to a different firm. Request a historical account statement covering August 2023 through December 2025. Some brokerages can provide this online; others may require a written request.
Does missing the April 6 deadline mean I can’t recover any money?
Missing the deadline means you can’t apply for lead plaintiff status, but you can still file a claim for damages once a settlement is finalized. However, you should monitor for settlement notifications. Courts typically issue claims periods of 60-90 days, so missing that deadline could permanently bar your recovery.
You Might Also Like
- Kyndryl Holdings Announces April 13, 2026 Deadline for Investor Class Action Applications
- Top 10 Class Action Settlements You Can Claim in April 2026
- Top 10 Class Action Settlements Available to Claim in April 2026